Ferring Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 300.00 Cr
as on 21-12-2024
- Paid Up Capital ₹ 272.85 Cr
as on 21-12-2024
- Company Age 13 Year, 26 Days
- Last Filing with ROC 31 Dec 2023
- Open Charges ₹ 2.00 Cr
as on 21-12-2024
- Revenue 19.91%
(FY 2022)
- Profit -26.50%
(FY 2022)
- Ebitda -6.80%
(FY 2022)
- Net Worth 4.23%
(FY 2022)
- Total Assets -11.28%
(FY 2022)
About Ferring Therapeutics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 December 2023. It's a company limited by shares with an authorized capital of Rs 300.00 Cr and a paid-up capital of Rs 272.85 Cr.
The company currently has active open charges totaling ₹2.00 Cr.
The Key Managerial Personnel (KMP) at Ferring Therapeutics Private Limited India is Piyali Das as COMPANY SECRETARY. Anindya Ghosh, Jens Regelin, and Robert Flury serve as directors at the Company.
- CIN/LLPIN
U74120MH2011PTC224424
- Company No.
224424
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Nov 2011
- Date of AGM
19 Jul 2024
- Date of Balance Sheet
31 Dec 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Social Media
Who are the key members and board of directors at Ferring Therapeutics?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anindya Ghosh  | Managing Director | 01-Dec-2016 | Current |
| Piyali Das | Company Secretary | 09-Sep-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jens Regelin  | Director | 13-Oct-2020 | Current |
| Robert Flury | Director | 13-Apr-2022 | Current |
Financial Performance of Ferring Therapeutics.
Ferring Therapeutics Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 19.91% increase. The company also saw a substantial fall in profitability, with a 26.5% decrease in profit. The company's net worth moved up by a moderate rise of 4.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ferring Therapeutics?
In 2022, Ferring Therapeutics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ferring Laboratories Private LimitedActive 8 years 11 monthsAnindya Ghosh and Jens Regelin are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Hongkong And Shanghai Banking Corporation Limited Creation Date: 20 Dec 2022 | ₹2.00 Cr | Open |
How Many Employees Work at Ferring Therapeutics?
Ferring Therapeutics has a workforce of 84 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ferring Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ferring Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
